Skip to main content
. Author manuscript; available in PMC: 2016 May 1.
Published in final edited form as: Mol Genet Metab. 2015 Feb 27;115(1):53–60. doi: 10.1016/j.ymgme.2015.02.006

Figure 2.

Figure 2

Figure 2

Figure 2

Histological and histomorphometric analyses of Losartan treated bones. Von Kossa staining of distal femurs of control (A) and Losartan treated (B) mice. (C) Quantification of the bone architecture indices. Bone perimeter (B.Pm), bone area (B.Ar), bone volume/tissue volume (BV/TV) and trabecular width (Tb.Wi) were increased significantly in Losartan treated group. Osteoblast parameters such as osteoblast number per bone surface (N.Ob/B.Pm) (D) and osteoblast surface per bone surface (Ob.S/BS) (E) were not affected by Losartan. Osteoclast number per bone surface (N.Oc/B.Pm) (F) and osteoclast surface per bone surface (Oc.S/BS) (G) were reduced in Losartan treated group. CTL: control, Los: Losartan-treated. * p<0.05, n=6 for control and treated group.